Search

A recent study conducted at Henan University in Luoyang, People's Republic of China, focused on the construction of compound protein lipid materials to potentially alleviate alcoholic fatty liver disease (AFLD). The study identified 21 core targets for epigallocatechin gallate (EGCG) that could improve the therapeutic effect of AFLD, particularly in cancer and prostate cancer pathways. By simulating the formation of composite lipid materials, the research provided new insights into addressing AFLD and developing products to mitigate the effects of alcohol. The study was funded by various organizations and has been peer-reviewed, offering valuable contributions to the field of bioinformatics and biotechnology. [Extracted from the article]

Researchers at the First Affiliated Hospital of China Medical University conducted a study on the safety and efficacy of dietary epigallocatechin gallate (EGCG) supplementation for managing obesity and non-alcoholic fatty liver disease (NAFLD). While EGCG has been associated with positive effects on health parameters in individuals with obesity and NAFLD, there are also reports suggesting potential hepatotoxicity. The study provides a comprehensive review of clinical findings on the effects of EGCG in treating obesity and NAFLD, focusing on treatment duration and dosage levels. For more information, the research article "The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates" can be accessed for free. [Extracted from the article]

A recent study from the University of Turin explores the role of the gut-liver axis in Non-Alcoholic Fatty Liver Disease (NAFLD) and the potential therapeutic effects of prebiotics in treating the condition. The research highlights the impact of gut microbiota on liver health and emphasizes the importance of maintaining a healthy intestinal barrier to prevent the progression of NAFLD. By focusing on dietary interventions like prebiotics, the study aims to address the underlying mechanisms of NAFLD and improve patient outcomes. [Extracted from the article]

Researchers from Fuzhou University in China have highlighted the potential of marine natural products in managing non-alcoholic fatty liver disease (NAFLD). With a global prevalence of 32.4%, NAFLD is a common chronic liver condition. The study explores how marine bioactive substances like polysaccharides and polyphenols can benefit liver health by addressing metabolic dysfunction. This research establishes a connection between marine compounds and the potential management of NAFLD, offering new avenues for therapeutic development. [Extracted from the article]

A study conducted in the U.S. from 1998 to 2020 analyzed hospitalization data of pediatric patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The research identified an increasing trend in hospitalization rates for NAFLD among pediatric populations and highlighted significant risk factors associated with mortality. Factors such as coagulopathy, age, diabetes, and obesity were found to impact mortality rates, while sex, race/ethnicity, and certain infections were not significantly associated with mortality. Further research is recommended to gather more data on this patient population. [Extracted from the article]

A patent application titled "Hepatic Organoids" was published online by inventors from the Netherlands, focusing on modeling non-alcoholic fatty liver disease (NAFLD) in human hepatocyte organoids. The application highlights the importance of genetic and diet-driven factors in lipid accumulation and steatosis, as well as the potential role of FADS2 in regulating lipid metabolism. The organoids described in the patent aim to provide a model system for studying lipid homeostasis and related diseases, offering insights into NAFLD, NASH, and other fatty liver disorders. [Extracted from the article]

A recent study conducted by the Karolinska Institute explored the relationship between loneliness, social isolation, and the risk of non-alcoholic fatty liver disease (NAFLD). The study, which included over 400,000 participants from the UK Biobank, found that both loneliness and social isolation were independently associated with an increased risk of NAFLD. The research also highlighted the role of lifestyle, depression, and inflammatory factors as potential mediators of this association. This study underscores the importance of addressing loneliness and social isolation in the prevention and management of NAFLD. [Extracted from the article]

A recent study conducted at Hashemite University in Jordan found that there is a low level of awareness about non-alcoholic fatty liver disease (NAFLD) among parents of overweight and obese children. The research highlighted the need for effective awareness programs by health authorities to address this issue. The study showed that higher education levels, income levels, and working in the medical field were associated with higher levels of NAFLD knowledge among participants. This information is important for understanding and addressing the prevalence of NAFLD in children globally. [Extracted from the article]

Researchers from Nanchang University have conducted a study on alcoholic fatty liver disease, focusing on the role of the adipokine Omentin-1 in preserving autophagy through the AMPKa/mTOR signaling pathway. The study involved feeding mice a high-fat diet to induce nonalcoholic fatty liver disease and treating them with Omentin-1, which resulted in reduced weight gain, improved glucose homeostasis, and decreased hepatic lipid accumulation. The research suggests that Omentin-1 could be a potential therapeutic agent for non-alcoholic fatty liver disease by preserving autophagy through the AMPKa/mTOR pathway. [Extracted from the article]

Researchers in Xiaogan, China, conducted a study to investigate the influencing factors of postoperative urinary tract infection in benign prostatic hyperplasia (BPH) patients with non-alcoholic fatty liver disease (NAFLD). The study analyzed clinical data from 159 patients and identified factors such as operation time, history of diabetes mellitus, and abnormal liver function as independent influencing factors for postoperative urinary tract infection. A prediction model based on these factors was established, showing promise in predicting postoperative urinary tract infection in BPH patients with NAFLD. [Extracted from the article]

Recent research from the Affiliated Hospital of Hangzhou Normal University focuses on the association between the triglyceride to high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus in individuals with non-alcoholic fatty liver disease (NAFLD). The study, conducted on 4,769 NAFLD patients, found that a higher TG/HDL-C ratio was positively associated with T2DM, indicating it could be a better predictor of diabetes risk than individual lipid parameters. Clinicians are advised to consider individuals with high triglyceride and low HDL-C levels when assessing T2DM risk in NAFLD cohorts. [Extracted from the article]

A recent study conducted at the Affiliated Hospital of Southeast University in China explored the relationship between vitamin D deficiency, insulin resistance, and non-alcoholic fatty liver disease (NAFLD). The research, based on data from the National Health and Nutrition Examination Survey (NHANES) and gene expression datasets, found that increased levels of vitamin D were associated with reduced insulin resistance and improved NAFLD status. The study identified specific genes involved in the insulin resistance pathway that were affected by changes in vitamin D levels. This research suggests that vitamin D may play a role in improving NAFLD by reducing insulin resistance. [Extracted from the article]

A patent application has been submitted for a compound aimed at treating non-alcoholic fatty liver disease (NAFLD) and related conditions. NAFLD affects a significant portion of the global population, with a high prevalence in developed nations like the United States. The compound targets hepatic steatosis and inflammation associated with NAFLD, offering potential therapeutic benefits for patients. The lack of FDA-approved therapies for NAFLD underscores the urgent need for effective treatments to address this growing health concern. [Extracted from the article]

Researchers at the University of Medicine and Pharmacy Craiova have published new findings on non-alcoholic fatty liver disease (NAFLD), highlighting its global impact as the main cause of chronic liver disease. The study emphasizes the importance of recognizing NAFLD as a key diagnostic factor for various conditions, including metabolic syndrome, insulin resistance, diabetes, and other health disorders. The researchers recommend increased awareness, collaboration among healthcare professionals, and screening for individuals at risk of NAFLD to address this growing public health challenge. [Extracted from the article]

A recent study conducted at King Faisal University in Saudi Arabia examined the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi adults and its relationship with obesity and metabolic health. The study found a high prevalence of NAFLD in individuals categorized as 'Overweight' and 'Obese,' with significant associations between NAFLD and higher BMI categories. Additionally, the research highlighted the importance of targeted public health interventions and early detection strategies for NAFLD in individuals with high BMI to mitigate its impact in Saudi Arabia. [Extracted from the article]

A study from Tabriz University of Medical Sciences explored the relationship between copper status, abdominal obesity indices, and liver function in patients with non-alcoholic fatty liver disease (NAFLD). The research found that low copper intake was associated with an increased likelihood of NAFLD, after adjusting for potential confounders. The study involved 80 overweight/obese patients with NAFLD and 80 healthy controls, highlighting differences in dietary intake and serum levels of liver aminotransferases, ferritin, copper, and ceruloplasmin between the two groups. The findings suggest a potential link between copper intake and the development of NAFLD. [Extracted from the article]

A recent study conducted by the Shandong Academy of Agricultural Sciences in China explored the use of medium-chain triglycerides (MCT) in alleviating non-alcoholic fatty liver disease (NAFLD). The research found that MCT supplements were more effective in improving weight gain, blood lipids, and hepatic lipid accumulation compared to traditional long-chain vegetable oils. The study highlighted the potential of MCT in treating NAFLD and provided new evidence for its application in this condition. [Extracted from the article]

A study conducted at Jeonbuk National University in South Korea explored the effects of fermented gold kiwifruit on mice with high-fat diet-induced obesity and hepatic steatosis. The research found that fermented gold kiwifruit supplementation significantly reduced levels of liver enzymes, cholesterol, triglycerides, and glucose in the mice. Additionally, the study suggested that fermented gold kiwifruit could potentially reduce the severity of non-alcoholic fatty liver disease by inhibiting fat synthesis, promoting fat breakdown, and suppressing inflammation in obese mice. [Extracted from the article]

Researchers from Shanghai University of Traditional Chinese Medicine conducted a study on the potential of puerarin in alleviating non-alcoholic fatty liver disease (NAFLD) using network pharmacology and experimental analysis methods. The study identified 189 target genes related to NAFLD and found that puerarin may modulate inflammatory pathways and regulate oxidative stress, thereby reducing liver inflammation and slowing the progression of NAFLD. The research suggests that puerarin could be developed as a potential treatment for NAFLD, either as an oral medication or in combination with other treatments to improve liver health in patients. [Extracted from the article]

Researchers at Nanjing Drum Tower Hospital in China conducted a study on the association between impaired sensitivity to thyroid hormone and non-alcoholic fatty liver disease (NAFLD) in diabetic individuals. The study included over 26,000 participants from a health screening program and over 8,000 hospitalized patients with type 2 diabetes. The findings indicated that impaired sensitivity to thyroid hormone was linked to an increased risk of developing NAFLD but a reduced risk of advanced fibrosis, specifically in diabetic individuals. The researchers suggest the need for further stratified studies on NAFLD based on diabetic status in the future. [Extracted from the article]

The patent application titled "Methods Of Treating Diseases Associated With Senescent Cell Accumulation" discusses the discovery of compounds that can address liver diseases and age-related conditions by targeting senescent cells. These compounds have the potential to treat diseases such as alcohol-induced liver disease, non-alcoholic fatty liver disease, and liver cancer. The application outlines methods for degrading specific proteins and killing senescent cells to address various health issues. The inventors aim to develop treatments that can reduce toxicity and improve clinical outcomes for patients with these conditions. [Extracted from the article]

Researchers from the Department of Kayachikitsa in New Delhi, India, have explored the potential role of Ayurveda interventions in managing Grade II Non Alcoholic Fatty Liver Disease (NAFLD). They presented a case study of a 59-year-old male who experienced relief from symptoms and improvement in liver health through Ayurveda-based therapies. The study highlights the effectiveness of individualized Ayurveda treatment in addressing NAFLD and emphasizes the importance of integrating traditional medicine into the clinical management of liver disorders. The research offers valuable insights into alternative approaches for managing liver conditions. [Extracted from the article]

A recent study examined the utility of the Non-Alcoholic Fatty Liver Disease Fibrosis Score in evaluating individuals with medically-complicated obesity. The research found that elevated ALT levels may indicate the presence of liver disease in individuals with high BMI. While there was a weak correlation between the NAFLD fibrosis score and fibrosis stage, further research is needed to determine the clinical implications for bariatric surgery in this population. The study was conducted by researchers at the Department of Medicine in Maryland, United States. [Extracted from the article]

The article discusses a clinical trial, NCT06705868, focusing on time-restricted eating (TRE) in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD). The trial aims to study the effects of TRE on body weight, fat mass, and the metabolism of toxic substances found in fruits and vegetables. Participants will follow a TRE dietary pattern for 3 months, with specific time restrictions on meal consumption and fruit and vegetable intake. The study compares TRE to a Standard of Care (SoC) approach for managing MASLD. [Extracted from the article]

A recent study conducted by researchers from Nanjing Medical University in China focused on the clinical value of the triglyceride glucose-body mass index (TyG-BMI) in patients with non-alcoholic fatty liver disease (NAFLD). The study included 393 patients diagnosed with NAFLD and found that higher TyG-BMI values were associated with a higher prevalence of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The researchers concluded that TyG-BMI could serve as a valuable noninvasive indicator for diagnosing NAFLD, stratifying risk, and monitoring disease progression. [Extracted from the article]

Researchers from Government College University Faisalabad in Pakistan have conducted a study on non-alcoholic fatty liver disease (NAFLD), focusing on the impact of poor dietary patterns on the condition. The study highlights the correlation between obesity, insulin resistance, and the development of NAFLD, emphasizing the importance of lifestyle changes, dietary modifications, and physical activity in managing the disease. The research underscores the significance of nutrition in the pathogenesis of NAFLD, recommending calorie restriction and balanced macronutrient intake for individuals with the condition. [Extracted from the article]

A study conducted at Islamic Azad University explored the impact of resistance training on hepatic bile acid, beta-klotho protein, and gene expression in male rats with non-alcoholic fatty liver disease (NAFLD). The research found that after eight weeks of resistance training, hepatic bile acid decreased significantly, while beta-klotho protein levels and the expression of certain genes related to cholesterol metabolism increased. The study suggests that resistance training may positively affect the signaling pathway involved in regulating bile acid biosynthesis and improving cholesterol metabolism in the body, potentially offering benefits for individuals with NAFLD. [Extracted from the article]

A study conducted at Shiraz University of Medical Sciences in Iran explored the therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damage. The research, which involved 30 mice, found that the treatments with CV and LBC significantly reduced kidney injury markers and improved kidney tissue structure. The study suggests that these probiotics may offer novel treatment approaches for managing NAFLD and its associated complications. [Extracted from the article]

A recent study conducted in Tamil Nadu, India, by researchers at the SRM Institute of Science and Technology focused on the relationship between preptin levels and non-alcoholic fatty liver disease (NAFLD) severity in patients with type 2 diabetes mellitus (T2DM). The study found that elevated serum preptin levels were significantly higher in T2DM patients with NAFLD, indicating a strong positive correlation with liver enzymes and NAFLD severity. These findings suggest that preptin may serve as a useful indicator for fibrosis progression in NAFLD and highlight the need for further research into its role in metabolic disorders. [Extracted from the article]

A patent has been issued for a method of diagnosing non-alcoholic fatty liver disease (NAFLD) using a panel of human blood protein biomarkers. NAFLD is a common liver disorder associated with obesity, affecting approximately 1 in 3 people in the US and UK. The patent aims to provide a minimally-invasive method for diagnosing, prognosing, and monitoring the progression of NAFLD using specific biomarkers, offering potential advancements in the field of liver disease diagnosis and treatment. [Extracted from the article]

The patent application titled "Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease" discusses the potential therapeutic use of ISM1 protein in addressing glucose and lipid-associated disorders, particularly non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The inventors propose that ISM1 protein can dissociate glucose uptake from lipid synthesis, potentially improving diabetes by decreasing insulin resistance and ameliorating hepatic steatosis. The application suggests that ISM1 protein could be administered to individuals to simultaneously treat hyperglycemia and hyperlipidemia, offering a new avenue for addressing metabolic syndrome. [Extracted from the article]

A recent study conducted at West China Hospital explored the relationship between body composition and the progression of non-alcoholic fatty liver disease (NAFLD) in patients with obesity. The research found that certain CT-based body composition indicators, such as high visceral fat index (VFI), were significantly associated with the progression of NAFLD in these patients. The study suggests that patients with specific body composition characteristics may require close monitoring and timely management to address the risk of NAFLD progression. [Extracted from the article]

Researchers from Second Hospital of Dalian Medical University have conducted a study on non-alcoholic fatty liver disease (NAFLD), a condition characterized by fat accumulation without excessive alcohol consumption. The research highlights the role of heat shock proteins (HSPs) in NAFLD pathogenesis, emphasizing their potential therapeutic applications. By understanding the molecular mechanisms of HSP-mediated protection in NAFLD, targeted therapies for this prevalent liver disorder may be developed. [Extracted from the article]

The University of Austral in Buenos Aires, Argentina, conducted research on the role of Secreted Protein Acidic and Rich In Cysteine (SPARC) in obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The study found that SPARC plays a significant role in adipogenesis, cellular metabolism, extracellular matrix modulation, and glucose and lipid metabolism. This research suggests that SPARC could be a potential target for therapeutic interventions or a biomarker for disease progression in these conditions. The findings were published in the Journal of Physiology and Biochemistry and have been peer-reviewed. [Extracted from the article]

Researchers at Suzhou Ninth People's Hospital conducted a study on lipid metabolism disorders, focusing on the impact of Hepatocyte nuclear factor 1 homeobox A (HNF1A) on type 2 diabetes combined with non-alcoholic fatty liver disease (NAFLD). The study found that knockdown of HNF1A improved glucose and lipid metabolism disorders in mice with high-fat diet and hyperglycemia, as well as modulated the PI3K/AKT/mTOR signaling pathway. The research suggests that targeting HNF1A could be beneficial in ameliorating type 2 diabetes and NAFLD. For more information, the study is published in the Journal of Men's Health. [Extracted from the article]

A recent report from researchers at the National and Kapodistrian University of Athens explores the bidirectional association between non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) based on endothelial dysfunction (EnD). NAFLD is linked to insulin resistance, obesity, and diabetes mellitus, increasing the risk of cardiovascular complications. The study aims to examine the pathophysiological mechanisms and genetic background underlying this relationship, discussing potential clinical implications and treatment options for patients with NAFLD and CAD. For more information, the full article is available in the International Journal of Molecular Sciences. [Extracted from the article]

A recent study conducted at Capital Medical University in Beijing, China, explored the effects of an 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor on non-alcoholic fatty liver disease in mice. The research found that the inhibitor improved glucolipid metabolism, insulin resistance, and reduced the severity of non-alcoholic fatty liver disease in mice. The study concluded that the inhibitor's mechanism likely involves decreased liver corticosterone levels and enhanced hepatocyte autophagy through specific signaling pathways. [Extracted from the article]

A new report discusses the global health issue of non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic dysfunctions such as obesity and type 2 diabetes. The report focuses on the gut-liver axis, a communication pathway between the liver and the gut, and explores the influence of gut microbiota, intestinal permeability, and inflammatory pathways in the development of NAFLD. The report also discusses potential therapeutic strategies, including fecal microbiota transplantation, phage therapy, and the use of specific probiotics, prebiotics, and postbiotics. Understanding these interactions can help identify potential therapeutic targets for NAFLD. [Extracted from the article]

Researchers at Lincoln Medical Center have published a new report on non-alcoholic fatty liver disease (NAFLD) and its connection to sarcopenia, a skeletal muscle disorder. Both conditions share common risk factors and underlying mechanisms, such as insulin resistance and chronic inflammation. The report explores the pathophysiological links between NAFLD and sarcopenia and discusses non-pharmacologic and emerging pharmacologic management strategies for patients with sarcopenia-associated NAFLD. These strategies include weight reduction, diet, alcohol and smoking cessation, physical activity, and the use of supplements and testosterone therapy. The research aims to improve care and intervention for patients with these conditions. [Extracted from the article]

A recent study conducted by researchers at NOVA Southeastern University explores the role of nuclear receptor superfamily members in non-alcoholic fatty liver disease (NAFLD) and potential approaches to treatment. NAFLD is characterized by the accumulation of fat in hepatocytes and can progress to non-alcoholic steatohepatitis (NASH), which is associated with inflammation. The study suggests that agents targeting nuclear receptors, such as thiazolidinediones (TZDs), may be potential treatments for NAFLD and NASH. However, further research is needed to develop tissue-specific ligands that do not interfere with other nuclear receptors. Currently, lifestyle changes, such as weight reduction and reduced fat intake, are the main treatment options for NAFLD. [Extracted from the article]

A recent study conducted by Babol University of Medical Sciences examined the thyroid function tests in overweight and obese children and adolescents with and without non-alcoholic fatty liver disease (NAFLD). The study found that there was no significant difference in the mean level of thyroid hormones between the two groups, and hypothyroidism was not observed. However, there were differences in the levels of AST, ALT, TG, HDL, and BMI between the two groups. The researchers suggest that further studies with larger sample sizes and longer durations are needed to explore this topic further. [Extracted from the article]

A study conducted by researchers from Shanxi Agricultural University in China explores the cross-generational effects of dietary sea buckthorn on non-alcoholic fatty liver disease (NAFLD) in the offspring of obese female mice. The study found that feeding sea buckthorn to maternal mice improved liver steatosis and lipid deposition in their offspring, reduced inflammation-related factors, inhibited the IkB/NF-kB pathway, and decreased the occurrence of NAFLD. The research suggests that sea buckthorn could be a novel strategy for treating NAFLD at the maternal level. [Extracted from the article]

A recent study conducted by researchers at Shandong First Medical University and Shandong Academy of Medical Sciences in China has explored the potential of a flavanone called Kurarinol (KUR) in treating non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). The study found that KUR effectively reduced lipid deposition and inflammation in hepatocytes, inhibited the proliferation of HCC cell lines, and suppressed NAFLD-HCC formation in mice. These effects were attributed to the suppression of epidermal growth factor receptor (EGFR) signaling. The findings suggest that KUR may be a promising strategy for preventing NAFLD-HCC through EGFR signaling suppression. [Extracted from the article]

A recent study conducted in Karachi, Pakistan examined the prevalence of non-alcoholic fatty liver disease (NAFLD) and the effectiveness of oral hypoglycemic drugs and lifestyle modifications in reducing fatty liver changes and liver enzymes in patients with type 2 diabetes mellitus. The study involved 200 patients, with 154 (77%) having NAFLD with type 2 diabetes and 46 (23%) having only fatty liver changes. The participants were prescribed different combinations of oral hypoglycemic agents and were advised to make lifestyle modifications. The combination of empagliflozin + metformin, along with lifestyle modifications, was found to be highly effective in reducing fatty changes and liver enzyme levels. [Extracted from the article]

A study conducted at the Second Affiliated Hospital in Shandong, China, explored the effects of Salvia miltiorrhiza bge. f. alba (SMBFA) on patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). The study found that SMBFA had a positive impact on glucose and lipid metabolism, insulin resistance, and liver function by modulating the STING signaling pathway. The research involved both human patients and mouse models, and significant improvements were observed in the group treated with SMBFA compared to the control group. This study provides valuable insights into potential treatments for T2DM-NAFLD. [Extracted from the article]

A recent study conducted by researchers at Government Medical College in Srinagar, India, examined the profile of spontaneous bacterial peritonitis (SBP) in patients with non-alcoholic fatty liver disease (NAFLD) cirrhosis. The study found that NAFLD is a significant contributor to chronic liver disease in the region, with SBP present in a majority of NAFLD cirrhosis patients. The research also observed a trend towards worse treatment outcomes and higher mortality rates in patients with NAFLD SBP. This study provides valuable insights into the impact of NAFLD on infection acquisition, antibiotic resistance patterns, and treatment outcomes in patients with cirrhosis. [Extracted from the article]

A recent study conducted at Zhejiang Ocean University in China has found that low molecular weight chitosan selenium nanoparticles (LCS-SeNPs) may have potential in addressing obesity and non-alcoholic fatty liver disease (NAFLD). The researchers discovered that LCS-SeNPs significantly inhibited fat accumulation and improved the intestinal barrier by increasing mucus secretion from goblet cells. Additionally, LCS-SeNPs reshaped the composition of intestinal flora, increasing the abundance of beneficial bacteria and decreasing the abundance of obesity-contributed bacteria. The modulation of intestinal microbiota by LCS-SeNPs influenced various metabolic pathways, providing a new theoretical foundation for utilizing selenium polysaccharides in the intervention of NAFLD. [Extracted from the article]